In-silico Study of Non-Specific EGFR Inhibitors for Targeting EGFRvIII in Glioblastoma

摘要: Glioblastoma (GBM) is known to be an extremely aggressive and malignant form of anaplastic arythrocytoma affecting the central nervous system in humans. Due its worse prognosis leading high mortality rate over years , there urgent need deviate from conventional surgical radiation therapeutic treatments delve into molecular targeted drug therapy techniques. Epiderma Growth Factor Receptor(EGFR) mutant version EGFRvIII are overexpressed case GBM resulting proliferation failure cell cycle arrest. expressed about 62% cases self-activating receptors independent ligands. This project undertaken for study potential inhibitors using bioinformatics tool. Thirteen commercially available EGFR were docked against protein stability results was based on their free binding energy values. The result compared with that Gefitinib Erlotinib, established EGFR. PD153035, Lavendustin A BIBX-1328BS found most suitable inhibitor which can proposed wet-lab testing as GBM. Further, few structural modifications two these ligands performed in-silico docking analysis repeated check more alternatives prove favourable inhibitors.